BioLineRx Ltd.
BLRX · NASDAQ
11/24/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $0 | $0 | $12 |
| % Growth | 1,526% | 19.2% | -97.8% | – |
| Cost of Goods Sold | -$1 | $0 | $0 | $6 |
| Gross Profit | $4 | $0 | $0 | $6 |
| % Margin | 83.4% | 76.3% | 86.7% | 48.2% |
| R&D Expenses | -$3 | $2 | $2 | $2 |
| G&A Expenses | $0 | $0 | $1 | $14 |
| SG&A Expenses | -$1 | $0 | $1 | $6 |
| Sales & Mktg Exp. | -$6 | $0 | $0 | -$8 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | -$8 | $3 | $3 | $10 |
| Operating Income | $0 | -$2 | -$2 | -$4 |
| % Margin | 0% | -757.6% | -937.6% | -37.7% |
| Other Income/Exp. Net | $1 | -$2 | $8 | $1 |
| Pre-Tax Income | $0 | -$4 | $5 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$4 | $5 | -$3 |
| % Margin | -117.8% | -1,296.1% | 2,010.6% | -27.1% |
| EPS | -1.47 | -1 | 0.065 | -0.041 |
| % Growth | -47% | -1,650.4% | 259.3% | – |
| EPS Diluted | -1.47 | -1 | 0.065 | -0.041 |
| Weighted Avg Shares Out | 4 | 4 | 80 | 80 |
| Weighted Avg Shares Out Dil | 4 | 4 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $2 |
| EBITDA | $0 | -$3 | $6 | $3 |
| % Margin | 0% | -1,147.4% | 2,240% | 26.4% |